From the Journals

Dose-escalated radiation therapy brings mixed results in prostate cancer


 

FROM JAMA ONCOLOGY

Patients in the high-dose arm less often went on to salvage therapy; however, investigators noted that they also had more toxic effects. compared with patients in the standard radiotherapy arm.

The advantage of avoiding or delaying the adverse effects of these therapies has to be weighed against the increased rate of RT-related morbidity with dose escalation,” Dr. Michalski and his associates wrote.

Dr. Michalski reported no conflicts of interest. The co-authors reported several conflicts of interest, including ties to ViewRay, Augmenix, Sanofi, AstraZeneca, AbbVie, and other companies.

SOURCE: Michalsky Jeff M et al. JAMA Oncol. 2018 Mar 15. doi: 10.1001/jamaoncol.2018.0039.

Pages

Recommended Reading

Enzalutamide shines in nonmetastatic castration-resistant prostate cancer
MDedge Hematology and Oncology
FDA approves apalutamide for castration-resistant nonmetastatic prostate cancer
MDedge Hematology and Oncology
Axitinib/pembrolizumab combo safe, effective against mRCC
MDedge Hematology and Oncology
Checkpoint inhibitors forge new treatment paradigm for metastatic bladder cancer
MDedge Hematology and Oncology
Prostate cancer survival similar with EBRT/brachytherapy or surgery, analysts claim
MDedge Hematology and Oncology
Avelumab safety compares with other checkpoint inhibitors
MDedge Hematology and Oncology
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Hematology and Oncology
Excellent prognosis for cystic RCC evaluated with radiologic threshold of greater than 50%
MDedge Hematology and Oncology
DNA repair gene mutations predict response to anti–PD-1/PD-L1 in urothelial cancer
MDedge Hematology and Oncology
Emerging data help inform immunotherapy for urothelial cancer
MDedge Hematology and Oncology